New Treatment for High-Risk Multiple Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug combination (Etenta-Isa-VRd) for patients newly diagnosed with high-risk multiple myeloma who are candidates for stem cell transplant. The goal is to see if this combination helps control the disease better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with multiple myeloma that is considered 'high-risk' (a more aggressive form)
- Your myeloma is measurable on blood tests or imaging scans
- You are healthy enough to undergo high-dose chemotherapy followed by stem cell transplant
- You have not received other anti-myeloma drugs yet (except for a steroid given in emergencies or one cycle of first-line treatment)
- Your blood counts and organ function are within acceptable ranges for the study
- You do not have certain rare myeloma variants or amyloidosis (a related protein disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.